AstraZeneca said it has ended several mid- and late-stage trials as part of portfolio prioritization after disappointing efficacy signals. The company’s first-quarter updates pointed to program-level pauses that could reduce the availability of certain life-cycle extension opportunities. Among the decisions, AstraZeneca also scrapped its FLAP inhibitor atuliflapon after a phase 2 trial failed to meet efficacy objectives in moderate-to-severe uncontrolled asthma. The company said the program was discontinued due to efficacy and removed from the pipeline. The retrenchment extends beyond atuliflapon, with AstraZeneca also ending work on multiple other programs across different stages, including a GH receptor antagonist and an ANGPTL3 inhibitor. Taken together, the updates reflect a renewed emphasis on reallocating resources when clinical risk is not adequately reducing—an operational move that can affect near-term development timelines for sponsors and partners.